Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of early stage triple negative breast cancer

被引：0
|
作者：
Chan, Nancy
Lu, Shou-en
Wang, Yue
Riedlinger, Gregory M.
Omene, Coral
George, Mridula
Malhotra, Jyoti
Kowzun, Maria
Eladoumikdachi, Firas G.
Potdevin, Lindsay B.
Kumar, Shicha
Matsuda, Kant
Desai, Shruti
Patel, Nayana
Toppmeyer, Deborah L.
Ganesan, Shridar
Hirshfield, Kim
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-15
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer
    Yao, Jia
    Pan, Shaobo
    Fan, Xiao
    Jiang, Xue
    Yang, Yuhong
    Jin, Jing
    Liu, Yu
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (04) : 202 - 207
  • [42] Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer
    Alvarez, I.
    Modolell, A.
    Mayordomo, J. I.
    Janariz, J.
    Centelles, M.
    Garcia, J. M.
    Puerto, P.
    Diego, C.
    Madronal, C.
    Burillo-R Andres, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Neoadjuvant biweekly chemotherapy with liposomal doxorubicin and docetaxel in patients with stage II-III breast cancer
    Alvarez, I
    Modolell, A.
    Mayordomo, J., I
    Heras, L.
    Villadiego, K.
    Rolfo, C. D.
    Garcia-Bueno, J. M.
    Pica, P.
    Murillo, L.
    Morales, S.
    Valera, P.
    Florian, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S229 - S229
  • [44] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+Breast Cancer
    Phadke, Sneha
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1779 - 1789
  • [45] Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes-Comprehensive Review
    Sringeri, R. Raxith
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (SUPPL 3) : 501 - 508
  • [46] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
    Sneha Phadke
    Current Oncology Reports, 2022, 24 : 1779 - 1789
  • [47] Impact of neoadjuvant systemic therapies on axillary response in early-stage triple-negative breast cancer
    Kook, Y.
    Minji, L.
    Moon, S.
    Ho, B. Seung
    Bae, S. J.
    Jeong, J.
    Ahn, S. G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1408 - S1408
  • [48] Receptor discordance after neoadjuvant chemotherapy with pembrolizumab in early-stage triple-negative breast cancer
    LeVee, Alexis
    Wong, Megan
    Flores, Sarah
    Ruel, Nora
    McArthur, Heather
    Waisman, James
    Mortimer, Joanne
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
    Saifi, Omran
    Chahrour, Mohamad A.
    Li, Zhuo
    Hoballah, Jawad
    Panoff, Joseph
    Vallow, Laura A.
    Zeidan, Youssef H.
    BREAST, 2022, 62 : 144 - 151
  • [50] Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients
    Adrada, B. E.
    Candelaria, R.
    Moulder, S.
    Lane, D.
    Santiago, L.
    Arribas, E.
    Hess, K. R.
    Valero, V.
    Thompson, A.
    Helgason, T.
    Ravenberg, E.
    Yang, W.
    Rauch, G. M.
    CANCER RESEARCH, 2019, 79 (04)
12345